MedPath

Incidence of immune checkpoint inhibitor-related myositis

Not Applicable
Conditions
Solid tumors
Registration Number
JPRN-UMIN000044960
Lead Sponsor
Yokohama City University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
12866
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Systematic review or meta-analysis articles. (2) Retrospective analysis. (3) Single prospective cohort study without a control group. (4) Non-RCT. (5) The republished research literature is excluded unless the research includes new findings related to adverse events listed in inclusion criteria. (6) Studies with no or insufficient safety results at the time of the literature search. (7) Studies published in languages other than English.

Study & Design

Study Type
Others,meta-analysis etc
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The odds ratio (OR) of any grade myositis will be calculated. Meta-analysis will be performed to compare the incidence of myositis between the treatment arm with ICIs and the arm with chemotherapy.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath